Can foreign capital and local pharmaceutical companies "hand in hand" become a new way out of volume procurement?

Pharmaceutical Network Industry Dynamics: The third batch of national volume procurement will be formally tendered on August 20.
From the "4 plus 7", "4 plus 7" expansion and the second batch of national volume procurement, the third batch of belt procurement is also considered by the industry to be the beginning of the normal collection, the future collection will become an unavoidable event in the pharmaceutical industry, pharmaceutical companies will also face price reduction and cost challenges.
while collecting will normalize attention, some pharmaceutical companies are exploring new ways out.
August 18, Shanghai Pharmaceutical Holdings said it had signed a strategic cooperation agreement with Ipsos China on Fusong (Polyglycol 4000).
the future, SSE Holdings will continue to promote the application of the product in the field and better meet the needs of patients in accordance with the cooperation arrangements between the two parties, including hospitals and retail.
As a leading enterprise in the field of pharmaceutical distribution in China, In order to strengthen further cooperation between the two sides, Shanghai Pharmaceutical Holdings will focus its own superior resources and further improve the accessability of patients through a network system in 24 provinces throughout the country.
it is understood that Fusong's original research enterprise is Beaufort-Ipson Group, the product was listed in France in 1995 as a permeable laxative in line with the physiological properties of the colon.
china in 1999 and in 2004 entered the health insurance list for the treatment of constipation symptoms in adults and children over 8 years of age, including 8 years of age.
2018, polyethyl glycol 4000 was scattered in China's public medical institutions terminal sales of more than 120 million yuan, of which France's Ipsos market share reached 48%.
In terms of the market pattern of the variety, in 2019, the original pharmaceutical company, Ipsom of France, still occupied the main market share of 28.89 percent, while Watson Pharmaceuticals, Warner Pharmaceuticals, Mahlong Pharmaceuticals and Sano Biopharmaceuticals accounted for 21.32 percent, 7.71 percent, 5.47 percent and 5.03 percent, respectively.
can be seen that the market share of the original pharmaceutical companies decreased compared with the previous year.
reasons behind it, including the promotion of volume procurement, to a certain extent, will accelerate the pace of imitation to replace the original research.
from the results of the second batch of volume procurement, the variety by Theron Pharmaceutical Group, Chongqing Sano Biopharmaceuticals, Chongqing Watson Pharmaceuticals, Hunan Warner Pharmaceuticals four medium-bid, the winning bid price is 7.39 yuan (10g x 10 10 bags), 8.45 yuan (10g x 10 bags), 14.09 yuan (10g x 15 bags), 35.48 yuan (10g x 30 bags).
original pharmaceutical research enterprise Ipson failed to win the bid.
Now Ipsum has announced a "hand in hand" with a local pharmaceutical company that the industry sees as a response to volume purchases, or wants to borrow the distribution network of Shanghai Pharmaceutical Holdings to expand sales to make up for the lack of market under the winning bid for volume purchases.
public information shows that Shanghai Pharmaceutical Holdings Co., Ltd., is a pharmaceutical distribution as the core of the national modern pharmaceutical supply chain service enterprises, operating network throughout the country 17 provinces and cities.
company distribution network covers more than 20,000 medical institutions in the country terminals, relying on a strong terminal network and service innovation, with favorable industry advantages, and in high-end supplies, DTP (high-value drug direct delivery) and SPD (pharmaceutical products hospital logistics services) and other new business areas have a strong industrial competitiveness.
In the industry's view, Ipson and Shanghai Pharmaceutical Holdings "hand in hand", is essentially the cooperation between manufacturers and channels, help manufacturers with the help of commercial channels to quickly cover the country, to achieve rapid release.
how much benefit this model can bring, it will take time to speak.
.